AstraZeneca entered a new kidney-focused drug discovery and development pact with CSPC Pharmaceutical, paying a $30 million upfront and agreeing to jointly discover and develop two kidney disease candidates. The arrangement is structured within AstraZeneca’s broader external innovation strategy, adding another collaboration layer to its longstanding China presence. The partners will work across discovery and development activities, with AstraZeneca funding early research through CSPC’s platform capabilities. The agreement also reinforces CSPC’s role as a go-to Chinese partner for large multinational biopharma in disease areas beyond oncology. For industry players, the deal highlights how kidney disease programs are attracting renewed external R&D investment as companies look for fresh assets that can move efficiently into clinical validation.